ArticleCancers2026
Prognostic Value of Regnase-1 in High-Grade Soft Tissue Sarcoma: Favourable in UPS, Yet Inverted in Adjuvantly Irradiated Patients.
Julie Zangarini, Axel Künstner, Florian Lenz, Lars Tharun, Jan Vorwerk, Niklas Gebauer, Jutta Kirfel, Hauke Busch, Bruno Christian Köhler, Eva Wardelmann and 5 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Julie ZangariniClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Axel KünstnerThe Research Group for Systems Biology, Institute for Experimental Dermatology (LIED), University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.ORCID 0000-0003-0692-2105 Florian LenzInstitute of Pathology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Lars TharunInstitute of Pathology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Jan VorwerkClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Niklas GebauerClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.ORCID 0000-0003-0566-4554 Jutta KirfelInstitute of Pathology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Hauke BuschThe Research Group for Systems Biology, Institute for Experimental Dermatology (LIED), University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.ORCID 0000-0003-4763-4521 Bruno Christian KöhlerClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Eva WardelmannGerhard Domagk Institute of Pathology, University Hospital Münster (UKM), 48149 Münster, Germany.ORCID 0000-0001-6788-4910 Dirk RadesDepartment of Radiation Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.ORCID 0009-0008-2046-4968 Anastassia LöserDepartment of Radiation Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Nikolas von BubnoffClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Cyrus KhandanpourClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.ORCID 0000-0003-4655-6269 Maxim KebenkoClinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.
Funding
Werner und Klara Kreitz-Stiftung. F289115 SVN 01.01.2022 - 31.03.2023
6 · The paper itselfAbstract
backgroundHigh-grade soft tissue sarcomas (STSs) are heterogeneous tumours lacking robust prognostic or predictive biomarkers. Regnase-1, an immune RNase, enhances antitumour immunity by limiting immunosuppressive tumour microenvironment (TME) components (e.g., myeloid-derived suppressor cells (MDSCs)), but remains unexplored in STS. As CD68
methodsImmunohistochemistry scoring of Regnase-1 and CD68
resultsIn UPS, Regnase-1-high predicted longer OS (17.0 months vs. not reached;
conclusionsRegnase-1 marked a pro-inflammatory TME and favourable outcome in UPS, but this effect may reverse upon radiotherapy.
Indexed as
CD68+ TAMshigh-grade STSICIPD-1PD-L1Regnase-1TIGITTILs
Identifiers
PMID42122218
PMCPMC13162679
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390